LB1520 Dupilumab improves symptoms of pain/discomfort in moderate-to-severe atopic dermatitis: EuroQol five dimensions questionnaire (EQ-5D) phase 3 clinical trials results

Pain has been suggested to be a major symptom for atopic dermatitis (AD) patients (pts). Dupilumab is approved in the EU, USA, Japan, and other countries for treatment of adults with inadequately controlled moderate-to-severe AD. Here we describe the burden related to symptoms of pain/discomfort in moderate-to-severe AD pts, and dupilumab efficacy in relieving these symptoms (assessed by EuroQol five dimensions questionnaire [EQ-5D]) across multiple phase 3 trials (LIBERTY AD SOLO 1&2 [pooled]: NCT02277743/NCT02277769; LIBERTY AD CHRONOS: NCT02260986; LIBERTY AD CAF É: NCT02755649).

https://www.jidonline.org/article/S0022-202X(18)32110-9/fulltext?rss=yes

Source: Journal of Investigative Dermatology - August 21, 2018 Category: Dermatology Authors: E. Simpson, J.I. Silverberg, L. Eckert, Z. Chen, M. Ardeleanu, B. Shumel, N. Graham, G. Pirozzi, B. Akinlade, A. Gadkari Tags: Clinical Research: Patient Outcomes Research Source Type: research